SCHEMBL935065

SCHEMBL935065

NC(=O)c1cccc(-c2ccccn2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.59
LMNA P02545 4/20 0.59
L3MBTL1 Q9Y468 4/20 0.59
CCR1 P32246 2/20 0.59
CCR5 P51681 2/20 0.59
CCR8 P51685 2/20 0.59
TP53 P04637 2/20 0.59
ALOX15 P16050 2/20 0.59
HTT P42858 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
HSP90AA1 P07900 2/20 0.59
ALPL P05186 1/20 0.59
ALPI P09923 1/20 0.59
ALPG P10696 1/20 0.59
MAPK1 P28482 1/20 0.59
P4HTM Q9NXG6 3/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
METAP1 P53582 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29074210 0.87 LMNA (0.45) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL9792961 0.87 PIM1 (0.50) KDM4ELMNAALOX15TDP1
SCHEMBL4811257 0.84 LMNA (0.62) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL3165743 0.82 ALDH1A1 (0.63) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL5997996 0.82 KDM4E (0.59) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL27873934 0.81 P2RX7 (0.54) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL20412771 0.81 KMT2A (0.68) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL6646668 0.79 KDM4E (0.50) KDM4ELMNAL3MBTL1CCR1CCR5
SCHEMBL1505348 0.78
SCHEMBL4914089 0.78 CES2 (0.67) KDM4ELMNAL3MBTL1MAPK1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108383779-B Preparation method of 3 '-aryl-2, 2' -bipyridine-6-formamide derivative 华侨大学 2021-02-02 CN claimed
CN-108383779-A A kind of preparation method of 3 '-aryl-bipy 2,2' bipyridyl -6- carboxamides derivatives 华侨大学 2018-08-10 CN claimed
US-8378108-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2013-02-19 US claimed
CN-116751195-B Bipyridine compound, pharmaceutically acceptable salt thereof, preparation method and application 杭州科兴生物化工有限公司 2025-03-07 CN disclosed
WO-2024199524-A1 COMPOUND AS PKMYT1 INHIBITOR 江苏星盛新辉医药有限公司 2024-10-03 WO disclosed
CN-116891456-A Heterocyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-10-17 CN disclosed
CN-116751195-A Bipyridine compound, pharmaceutically acceptable salt thereof, preparation method and application 杭州科兴生物化工有限公司 2023-09-15 CN disclosed
CN-110078661-B Preparation method of 3-alkenyl-2, 2' -bipyridine-6-formamide derivative 华侨大学 2022-07-29 CN disclosed
CN-110078661-B Preparation method of 3-alkenyl-2, 2' -bipyridine-6-formamide derivative 华侨大学 2022-07-29 CN disclosed
CN-110078662-B Preparation method of 3-acyl methyl-2, 2' -bipyridine-6-formamide derivative 华侨大学 2022-03-04 CN disclosed
CN-108383779-B Preparation method of 3 '-aryl-2, 2' -bipyridine-6-formamide derivative 华侨大学 2021-02-02 CN disclosed
CN-110078662-A A kind of preparation method of 3- acyl methyl-bipy 2,2' bipyridyl -6- carboxamides derivatives 华侨大学 2019-08-02 CN disclosed
CN-108383779-A A kind of preparation method of 3 '-aryl-bipy 2,2' bipyridyl -6- carboxamides derivatives 华侨大学 2018-08-10 CN disclosed
CN-108383779-A A kind of preparation method of 3 '-aryl-bipy 2,2' bipyridyl -6- carboxamides derivatives 华侨大学 2018-08-10 CN disclosed
EP-2681197-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2014-01-08 EP disclosed
WO-2012120415-A1 TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-09-13 WO disclosed
EP-2344474-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS Novartis AG (CH) 2011-07-20 EP disclosed
WO-2011008709-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2011-01-20 WO disclosed
WO-2010026124-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 WO disclosed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists HRH3, HRH4, HRH1 KDM4E 488/4885LMNA 3210/4885L3MBTL1 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.